LuAG-09222 is under clinical development by H. Lundbeck and currently in Phase I for Grass Pollen Allergy. According to GlobalData, Phase I drugs for Grass Pollen Allergy have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LuAG-09222’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LuAG-09222 is under development for the treatment of grass pollen allergic rhiniti, chronic and frequent episodic migraine. It is administered through intravenous route. It is a monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide-38(PACAP-38). It is developed based on ABS(antibody selection) technology.
H. Lundbeck overview
H. Lundbeck (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company’s products are indicated for the treatment of Alzheimer’s disease, migraine, depression, Parkinson’s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, depression, anxiety, psychosis, and epilepsy, among others. It operates production facilities in Denmark, Italy, and France, and research centers in the US and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies, and hospitals in Italy, China, Spain, Canada, France, South Korea, Australia, the US, and other countries. Lundbeck is headquartered in Valby, Denmark.
For a complete picture of LuAG-09222’s drug-specific PTSR and LoA scores, buy the report here.